Skip to content

1st line chemotherapy of XELoda/OXaliplatin for advanced Gastric cancer PI

1st line chemotherapy of XELoda/OXaliplatin for advanced Gastric cancer PI - G-XELOX PI study

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000015951
Enrollment
9
Registered
2014-12-15
Start date
2014-12-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Sponsors

Kobe City Medical Center General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)histlogically proven gastric adenocarcinoma 2)chemotherapy naive 3)Performance status must be Eastern Cooperative Oncology Group (ECOG) 0, or 1 4)Age >= 20 years 5)Patients who can take medication orally 6)Adequate bone marrow, hepatic, renal, cardiac and respiratory functions 7)HER2 negative or unknown 8)Written informed consent

Exclusion criteria

Exclusion criteria: 1) active synchronous or metachronous malignancy other than carcinoma in situ 2) pregnant or nursing 3) severe mental disorders 4) systemic steroid user 5) diabetes mellitus, uncontrolled or controlled with insulin 6) history of myocardial infarction, unstable angina within 3 months prior to the registration 7) serious coexisting illness 8) active infection 9) peripheral neuropathy greater than Grade 2 10) ileus 11) massive pleural effusion or ascites

Design outcomes

Primary

MeasureTime frame
safety

Countries

Japan

Contacts

Public ContactHironaga Satake

Kobe City Medical Center General Hospital Division of Oncology / Gastroenterology,

hsatake@kcho.jp+81-(0)78-302-4321

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026